Over the past 15 years, Byrock Technologies has dedicated itself to the development of innovative solutions capable of both therapeutic and preventative action against equine laminitis. Our journey began with PTP-100, which laid the foundation for PTP-101 and, ultimately, PTP-102. With each progressive innovation, we have leveraged our extensive industry knowledge and unwavering commitment to providing safe and effective veterinary care. Each of these products has demonstrated strong efficacy in addressing equine laminitis, establishing a solid foundation in combating this debilitating disease.
Our revolutionary approaches are deeply rooted in rigorous scientific research, ensuring that we lead the market in delivering breakthrough therapeutics.
Laminitis is one of the most severe and painful conditions affecting horses, capable of impacting any horse at any stage of their life, with certain breeds being more susceptible. The disease involves inflammation of the lamina within the hoof, which plays a crucial role in connecting the hoof to the coffin bone. This connection is robust, akin to a ‘velcro’ bond, yet under certain conditions, it can fail, precipitating the onset of laminitis.
Recognising the urgency of this condition, Byrock Technologies has developed PTP-102, the first of its kind treatment designed specifically to prevent and to mitigate the long-term effects of laminitis. This pioneering product, which has proven extremely effective in clinical trials, stands as a testament to our commitment to innovation. Our proactive approach not only enhances treatment outcomes but also significantly improves the prognosis for affected horses, ensuring better quality of life and performance.
As we continue to push the boundaries of veterinary medicine, Byrock Technologies remains at the forefront of technological advancements, with a clear focus on transforming the landscape of equine health care.
PTP-102
The only effective treatment for laminitis* in horses.
“PTP-102 exhibited notable success in treating laminitis by targeting the deactivation of MMPs, thereby stimulating the reconstruction of damaged lamellar and basement structures. Its impact on alleviating clinical symptoms and systemic inflammatory responses also significant.” ¬ Dr. Maimaiti Tuniyazi | Jilin University
PTP-102 is a novel synthetic nonglucocorticoid 21-aminosteroid that is designed to inhibit the range of metalloprotease enzymes and inflammatory cytokines which are the principal causative agents of equine laminitis.
PTP-102 can be used both therapeutically and prophylactically against laminitis. It has shown the ability to prevent and treat equine laminitis in just 72 hours. A condition that has long been considered untreatable.
PTP-102 is to be administered intravenously by a qualified vet.
PTP-102 is a unique treatment because it specifically targets the biochemical pathways involved in laminitis, offering a more focused approach compared to general anti-inflammatory or pain relief medications.
*Laminitis: definition
Laminitis is a disease that affects the feet of hooved animals (ungulates) and it is found mostly in horses and cattle. Clinical signs include foot tenderness progressing to inability to walk, increased digital pulses, and increased temperature in the hooves. Severe cases with outwardly visible clinical signs are known by the colloquial term founder, and progression of the disease may lead to perforation of the coffin bone through the sole of the hoof, requiring aggressive treatment or euthanasia.
https://dictionary.babylon-software.com/laminitis/